Contradicting results on the effect of abacavir (ABC) on
hepatitis C virus (HCV) treatment responses in HIV/HCV co-infected patients
have been reported. We evaluated the influence of ABC on the response to
pegylated interferon (pegIFN) and ribavirin (RBV)-containing HCV treatment in
HIV/HCV co-infected patients in a large European cohort collaboration,
including data from different European countries.
HIV/HCV co-infected patients were included if they were aged
≥16 years, received pegIFN alfa-2a or 2b and RBV combination treatment and
were enrolled in the COHERE cohort collaboration. Logistic regression was used
to evaluate the impact of abacavir on achieving a sustained virologic response
(SVR) to HCV treatment.
In total 1309 HIV/HCV co-infected patients who had received
HCV therapy were included, of whom 490 (37 %) had achieved an SVR. No
statistically significant difference was seen for patients using ABC-containing
regimens compared to patients using an emtricitabine + tenofovir
(FTC + TDF)-containing backbone, which
was the most frequently used backbone. In the multivariate analyses, patients
using a protease inhibitor (PI)-boosted regimen were less likely to achieve an
SVR compared to patients using a non-nucleoside reverse-transcriptase inhibitor
(NNRTI)-based regimen (OR: 0.61, 95 % CI: 0.41–0.91). The backbone
combinations zidovudine&lamivudine (AZT + 3TC) and
stavudine&lamivudine (d4t + 3TC) were associated with lower
SRV rates (0.45 (0.24–0.82)
and 0.46 (0.22–0.96),
respectively).
The results of this large European cohort study validate
that SVR rates are generally not affected by ABC. Use of d4T or AZT as part of
the HIV treatment regimen was associated with a lower likelihood of achieving
an SVR.
Full article at: http://goo.gl/99tVkR
By:
Stichting HIV Monitoring, Meibergdreef 9, Amsterdam, 1105AZ, The
Netherlands
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment